Related Experiment Video
Updated: Nov 21, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Molecular mechanism study of EGFR allosteric inhibitors using molecular dynamics simulations and free energy
Xiaoyun Wu1, Qian Guo1, Qinlan Li1
1Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, PR China.
Abstract:
ABTRACTThe epidermal growth factor receptor (EGFR) kinase inhibitors Gefitinib, Erlotinib, Afatinib and Osimertinib have been approved for the treatments of non-small cell lung cancer patients harboring sensitive EGFR mutations, but resistance arises rapidly. To date all approved EGFR inhibitors are ATP-competitive inhibitors, highlighting the need for therapeutic agents with alternative mechanisms of action. Allosteric kinase inhibitors offer a promising new therapeutic strategy to ATP-competitive inhibitors. The mutant-selective allosteric EGFR inhibitors EAI045 exhibited higher potency for EGFRL858R&T790M compared to WT, which was also effective in EGFR-mutant models including those harboring the C797S mutation. However, it was not effective as a single-agent inhibitor, and require the co-administration of the anti-EGFR antibody Cetuximab. Further efforts produced a more potent analog JBJ-04-125-02, which can inhibit cell proliferation as a single-agent inhibitor. In the present study, molecular dynamics simulations and free energy calculations were performed and revealed the detailed inhibitory mechanism of JBJ-04-125-02 as more potent EGFR inhibitor. Moreover, the energy difference between HOMO and LUMO calculated by DFT implied the higher interaction of JBJ-04-125-02 than EAI045 in the active site of the EGFR. The identified key features obtained from the molecular modeling enabled us to design novel EGFR allosteric inhibitors.Communicated by Ramaswamy H. Sarma.
Insights
New allosteric inhibitors targeting the epidermal growth factor receptor (EGFR) show promise for non-small cell lung cancer. JBJ-04-125-02 is a potent single-agent inhibitor, offering a new therapeutic strategy beyond ATP-competitive drugs.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Approved epidermal growth factor receptor (EGFR) kinase inhibitors face rapid resistance due to acquired mutations.
- Current EGFR inhibitors are ATP-competitive, necessitating novel mechanisms of action like allosteric inhibition.
Purpose of the Study:
- To investigate the inhibitory mechanism of a novel mutant-selective allosteric EGFR inhibitor, JBJ-04-125-02.
- To understand the molecular basis for JBJ-04-125-02's enhanced potency compared to previous allosteric inhibitors.
- To guide the design of next-generation allosteric EGFR inhibitors.
Main Methods:
- Molecular dynamics (MD) simulations were employed to analyze the inhibitory mechanism.
- Free energy calculations elucidated the binding interactions within the EGFR active site.
- Density Functional Theory (DFT) was used to calculate the Highest Occupied Molecular Orbital (HOMO) and Lowest Unoccupied Molecular Orbital (LUMO) energy difference.
Main Results:
- JBJ-04-125-02 demonstrated potent single-agent inhibitory activity against EGFR, including resistance mutations like C797S.
- MD simulations and free energy calculations revealed the detailed mechanism of JBJ-04-125-02's potent inhibition.
- DFT analysis indicated stronger interactions of JBJ-04-125-02 with the EGFR active site compared to EAI045, evidenced by HOMO-LUMO energy differences.
Conclusions:
- JBJ-04-125-02 represents a significant advancement in allosteric EGFR inhibitor development, overcoming limitations of earlier compounds.
- The molecular insights gained provide a foundation for designing novel and more effective allosteric EGFR inhibitors for cancer therapy.
- This study highlights the potential of allosteric inhibition as a viable strategy against EGFR-mutant cancers, including those with resistance mutations.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
01:08Allosteric Regulation
01:58Cooperative Allosteric Transitions
01:58Cooperative Allosteric Transitions
01:30Enzyme Inhibition
01:19Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
02:38Mitogens and the Cell Cycle